ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference

Rhea-AI Summary

ProQR Therapeutics N.V. (Nasdaq: PRQR) announced its management will present at the HC Wainwright Global Life Sciences Conference on March 9, 2021. A webcast of the presentation will be available on the company's website. ProQR focuses on developing transformative RNA therapies for inherited retinal diseases. The company emphasizes its commitment to creating impactful treatments for genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome, and retinitis pigmentosa.

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will present during a fireside chat at the upcoming virtual HC Wainwright Global Life Sciences Conference. A webcast of the presentation will be accessible on demand from the “Investors & Media” section of ProQR’s website (www.proqr.com) under ‘Events’, beginning March 9, 2021.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in this conference. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.

Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 535 7743
hans@lifesciadvisors.com

Media Contact:
Cherilyn Cecchini, MD
LifeSci Communications
T: +1 646 876 5196
ccecchini@lifescicomms.com

 

FAQ

What is the significance of ProQR's presentation at the HC Wainwright Global Life Sciences Conference?

ProQR's presentation highlights its ongoing efforts in advancing RNA therapies for inherited retinal diseases, which may attract investor interest and insights into its pipeline.

When will ProQR's presentation be available for viewing?

The webcast of ProQR's presentation will be accessible on demand starting March 9, 2021.

What diseases does ProQR Therapeutics focus on treating?

ProQR Therapeutics specializes in developing RNA therapies for severe genetic rare diseases, including Leber congenital amaurosis 10, Usher syndrome, and retinitis pigmentosa.

What type of therapies is ProQR developing?

ProQR is creating transformative RNA therapies using its proprietary RNA repair platform technologies.